What’s the financial overview for H. Lundbeck A/S?

H. Lundbeck A/S’s market cap stands at $0.004 trillion right now. The company’s trailing twelve-month earnings per share EPS is $0.55, with a dividend yield of 2.49%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

How can I analyze historical data?

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

What does H. Lundbeck A/S Stock ROE tell us?

H. Lundbeck A/S stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

What is per share price for H. Lundbeck A/S?

The H. Lundbeck A/S stock per share price is $5.51.

H. Lundbeck A/S

HLBBF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$5.51

$0.00(0.00%)

H. Lundbeck A/S (HLBBF) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for H. Lundbeck A/S (HLBBF), featuring income statements, balance sheets, and cash flow data.

Revenue Growth

10.51%

↑ 10.51%

Operating Income Growth

2.35%

↑ 2.35%

Net Income Growth

37.25%

↑ 37.25%

Operating Cash Flow Growth

-18.48%

↓ 18.48%

Operating Margin

18.10%

↑ 18.10%

Gross Margin

81.55%

↑ 81.55%

Net Profit Margin

14.82%

↑ 14.82%

ROE

14.28%

↑ 14.28%

ROIC

9.62%

↑ 9.62%

H. Lundbeck A/S (HLBBF) Income Statement & Financial Overview

Analyze H. Lundbeck A/S’s HLBBF earnings with segmented quarterly and yearly financial statement figures.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Revenue	$5.54B	$5.72B	$5.48B	$5.29B
Cost of Revenue	$1.07B	$1.09B	$1.10B	$1.06B
Gross Profit	$4.47B	$4.63B	$4.38B	$4.23B
Gross Profit Ratio	$0.81	$0.81	$0.80	$0.80
R&D Expenses	$1.12B	$1.52B	$889.00M	$933.00M
SG&A Expenses	$2.76B	$2.29B	$2.46B	$2.02B
Operating Expenses	$4.29B	$3.82B	$3.35B	$2.95B
Total Costs & Expenses	$5.36B	$4.91B	$4.45B	$4.01B
Interest Income	$0.00	$0.00	$0.00	$29.00M
Interest Expense	$0.00	$0.00	$4.00M	$0.00
Depreciation & Amortization	$0.00	$0.00	$467.00M	$468.00M
EBITDA	$739.00M	$811.00M	$1.004B	$1.76B
EBITDA Ratio	$0.13	$0.14	$0.18	$0.33
Operating Income	$177.00M	$811.00M	$1.03B	$1.28B
Operating Income Ratio	$0.03	$0.14	$0.19	$0.24
Other Income/Expenses (Net)	$503.00M	-$79.00M	-$30.00M	$29.00M
Income Before Tax	$680.00M	$732.00M	$1.00B	$1.31B
Income Before Tax Ratio	$0.12	$0.13	$0.18	$0.25
Income Tax Expense	$90.00M	-$45.00M	$230.00M	$301.00M
Net Income	$590.00M	$777.00M	$770.00M	$1.006B
Net Income Ratio	$0.11	$0.14	$0.14	$0.19
EPS	$0.59	$0.78	$0.78	$1.01
Diluted EPS	$0.59	$0.78	$0.78	$1.01
Weighted Avg Shares Outstanding	$991.23M	$996.15M	$987.18M	$992.01M
Weighted Avg Shares Outstanding (Diluted)	$991.23M	$996.15M	$987.18M	$992.01M

Over the last four quarters, H. Lundbeck A/S achieved steady financial progress, growing revenue from $5.29B in Q1 2024 to $5.54B in Q4 2024. Gross profit stayed firm with margins at 81% in Q4 2024 versus 80% in Q1 2024. Operating income totaled $177.00M in Q4 2024, maintaining a 3% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $739.00M. Net income dropped to $590.00M, with EPS at $0.59. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;